Bavarian Nordic Receives 65 mEUR Contract to Supply Smallpox Vaccines for EU Strategic Reserve
April 29 2024 - 3:30PM
Bavarian Nordic Receives 65 mEUR Contract to Supply Smallpox
Vaccines for EU Strategic Reserve
COPENHAGEN, Denmark, April 29,
2024 – Bavarian Nordic A/S (OMX: BAVA) today announced the
award of a contract valued at EUR 65 million to supply its MVA-BN®
smallpox vaccine to the strategic reserve within the European Union
(EU) in 2025. This third, and larger order follows two previous
orders, received in 2023 and delivered in 2024, for smallpox
vaccines to rescEU stockpiles across Europe and will help to expand
the EU’s capability to respond to future biological threats and
emergencies by enabling rapid deployment of medical countermeasures
to its member states.
Paul Chaplin, President & CEO of Bavarian
Nordic, said: “Public health crises in recent years have
demonstrated the need for building a robust infrastructure across
EU nations for deploying vaccines in emergencies. We applaud the
rescEU initiative, which aims to reinforce the EU’s ability to
respond to future health crises and through incremental orders for
our smallpox vaccine will further strengthen the biological
preparedness across the region. We are pleased to expand this
collaboration, as we further increase our commitments to supplying
smallpox vaccines to a growing customer base, while also adding to
our base of secured contracts for 2025.”
About the smallpox
vaccineMVA-BN or Modified Vaccinia Ankara-Bavarian Nordic
(marketed under the brand names JYNNEOS®, IMVANEX® and IMVAMUNE®)
is a non-replicating smallpox and mpox vaccine. The vaccine is
approved by the FDA, EC, Health Canada, MHRA and Swissmedic and has
also obtained emergency use authorization in other territories for
use during the mpox outbreak. The vaccine was originally developed
in collaboration with the U.S. government to ensure supply of a
smallpox vaccine for the entire population, including
immunocompromised individuals who are not recommended vaccination
with traditional replicating smallpox vaccines.
About rescEURescEU is part of
the EU Civil Protection Mechanism, established by the European
Commission as a safety net to protect citizens from disasters and
manage emerging risks. It includes, among others, reserves of
medical countermeasures which can be deployed in chemical,
biological, radiological, and nuclear (CBRN) emergencies. The EU
sanitary stockpiles are built in cooperation with the Health
Emergency Preparedness and Response Authority (HERA) created by the
EU at the end of 2021 following the COVID-19 crisis. Read
more:https://civil-protection-humanitarian-aid.ec.europa.eu/what/civil-protection/resceu_en
https://health.ec.europa.eu/health-emergency-preparedness-and-response-hera_en
About Bavarian NordicBavarian
Nordic is a fully integrated vaccine company with a mission to
protect and save lives through innovative vaccines. We are a global
leader in smallpox and mpox vaccines, supplied to governments to
enhance public health preparedness and have a strong portfolio of
vaccines for travelers and endemic diseases. For more information
visit www.bavarian-nordic.com.
Forward-looking statements This
announcement includes forward-looking statements that involve
risks, uncertainties and other factors, many of which are outside
of our control, that could cause actual results to differ
materially from the results discussed in the forward-looking
statements. Forward-looking statements include statements
concerning our plans, objectives, goals, future events, performance
and/or other information that is not historical information. All
such forward-looking statements are expressly qualified by these
cautionary statements and any other cautionary statements which may
accompany the forward-looking statements. We undertake no
obligation to publicly update or revise forward-looking statements
to reflect subsequent events or circumstances after the date made,
except as required by law.
ContactsEurope: Rolf Sass
Sørensen, Vice President Investor Relations,
rss@bavarian-nordic.com, Tel: +45 61 77 47 43US: Graham Morrell,
graham@paddockcircle.com, Tel: +1 781 686 9600
Company Announcement no. 10 / 2024
Bavarian Nordic AS (TG:BV3)
Historical Stock Chart
From Apr 2024 to May 2024
Bavarian Nordic AS (TG:BV3)
Historical Stock Chart
From May 2023 to May 2024